Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

Bone

Volumn 44, Issue 5, 2009, Pages 758-765

  Harris, S T ^a   Reginster, J Y ^b   Harley, C ^c   Blumentals, W A ^d   Poston, S A ^e   Barr, C E ^d   Silverman, S L ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c i3 Innovus   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Hip fracture; Ibandronate; Nonvertebral fracture; Osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTRATEST; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; PIPERAZINE ESTRONE SULFATE; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DATA ANALYSIS; DATA BASE; DRUG DOSE REGIMEN; DRUG EFFICACY; EVALUATION; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES;

EID: 63449137386     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.01.002     Document Type: Article

References (30)

1. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General. 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/. Accessed June 30, 2008.
2. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 11 (2000) 556-561
3. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Fracture risk following an osteoporotic fracture. Osteoporos. Int. 15 (2004) 175-179
4. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15 (2004) 38-42
5. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al., FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J. Clin. Endocrinol. Metab. 85 (2000) 4118-4124
6. Chesnut C.H., Ettinger M.P., Miller P.D., Baylink D.J., Emkey R., Harris S.T., et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr. Med. Res. Opin. 21 (2005) 391-401
7. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19 (2004) 1241-1249
8. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
9. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int. 74 (2004) 129-135
10. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al., Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282 (1999) 1344-1352
11. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al., Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344 (2001) 333-340
12. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 11 (2000) 83-91
13. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis. 65 (2006) 654-661
14. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
15. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. 71 (2002) 103-111
16. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 54 (2006) 1838-1846
17. Delmas P.D., McClung M.R., Zanchetta J.R., Racewicz A., Roux C., Benhamou C.L., et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42 (2008) 36-42
18. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 20 (2005) 1315-1322
19. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., et al., Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
20. Harris S.T., Blumentals W.A., and Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr. Med. Res. Opin. 24 (2008) 237-245
21. Cranney A., Wells G.A., Yetisir E., Adami S., Cooper C., Delmas P.D., et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20 (2009) 291-297
22. Papapoulos S.E., and Schimmer R.C. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann. Rheum. Dis. 66 (2007) 853-858
23. Zaidi M., Epstein S., Harris S.T., Kohles J.D., and Chesnut C.H. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Ann. N. Y. Acad. Sci. 1117 (2007) 273-282
24. Lindsay R. Beyond clinical trials: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis. Bone 40 (2007) S32-S35
25. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., and Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos. Int. 18 (2007) 25-34
26. Cadarette S.M., Katz J.N., Brookhart M.A., Sturmer T., Stedman M.R., and Solomon D.H. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann. Intern. Med. 148 (2008) 637-646
27. Cramer J.A., Silverman S.L., and Gold D.T. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr. Med. Res. Opin. 23 (2007) 2369-2377
28. Miller P.D., Epstein S., Sedarati F., and Reginster J.Y. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr. Med. Res. Opin. 24 (2008) 207-213
29. Sebba AI, Emkey RK, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Bone 2009, doi:10.1016/j.bone.2008.10.052.
30. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 312 (1996) 1215-1218